Testing CT-202 for Triple Negative Breast, Colorectal, and Bladder Cancers
Part of Cancer, Digestive system, Skin clinical trials.
This early-stage trial tests a new antibody drug called CT-202 in patients whose cancer has come back after standard treatments. The drug is designed to target cancer cells that have a specific protein called Nectin-4, and may help the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer (triple negative breast, colorectal, or bladder/urothelial) must have returned or progressed after you've already tried standard treatments
- You must have measurable tumors that can be seen on scans (per RECIST 1.1 criteria)
- You must be in reasonable overall health with a life expectancy of at least 12 weeks
- Your organs (liver, kidneys, heart, bone marrow) must be working adequately
- You cannot have had severe skin reactions to previous cancer treatments
- You must not be enrolled in another experimental trial at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial tests a new drug, MR001, for people with triple-negative breast cancer that has come back or spread. It's for those who've already tried at least one type of treatment.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.